VaccinesNews.net

Vaccines Xagena

Xagena Mappa
Xagena Newsletter
OncologiaMedica.net
Medical Meeting

Since April 2021, increased cases of myocarditis and pericarditis have been reported in the United States after mRNA COVID-19 vaccination ( Pfizer-BioNTech and Moderna ), particularly in adolescents a ...


EMA’s human medicines committee ( CHMP ) has recommended granting an extension of indication for the COVID-19 vaccine Comirnaty ( Pfizer / BioNTech ) to include use in children aged 12 to 15. The va ...


The FDA ( U.S. Food and Drug Administration ) has expanded the emergency use authorization ( EUA ) for the Pfizer-BioNTech COVID-19 Vaccine for the prevention of coronavirus disease 2019 ( COVID-19 ) ...


EMA’s safety committee ( PRAC ) has concluded that a warning about unusual blood clots with low blood platelets should be added to the product information for COVID-19 Vaccine Janssen. PRAC has also ...


EMA’s safety committee, PRAC, has concluded its preliminary review of a signal of blood clots in people vaccinated with COVID-19 Vaccine AstraZeneca at its extraordinary meeting of 18 March 2021. ...


The FDA ( U.S. Food and Drug Administration ) has issued an emergency use authorization ( EUA ) for the third vaccine for the prevention of coronavirus disease 2019 ( COVID-19 ) caused by severe acute ...


EMA ( European Medicines Agency ) has recommended granting a conditional marketing authorisation for COVID-19 Vaccine AstraZeneca to prevent coronavirus disease 2019 ( COVID-19 ) in people from 18 yea ...


The COVID-19 pandemic has caused significant morbidity and mortality throughout the world, as well as major social, educational and economic disruptions. There is an urgent global need for effective ...


All reports of suspected adverse reactions with fatal outcome following COVID-19 vaccination are carefully assessed. The reports have suggested that common adverse reactions to mRNA ( messenger RNA ) ...


During December 14–23, 2020, after administration of 1,893,360 first doses of Pfizer-BioNTech COVID-19 vaccine ( 1,177,527 doses in females, 648,327 doses in males, and 67,506 doses missing sex ), rep ...


The safety of Comirnaty was evaluated in participants 16 years of age and older in 2 clinical studies that included 21,744 participants that have received at least one dose of Comirnaty. In Study 2, ...


EMA ( European Medicines Agency ) has granted conditional marketing authorisation for the vaccine Comirnaty, developed by BioNTech and Pfizer, to prevent coronavirus disease 2019 ( COVID-19 ) in peopl ...


EMA ( European Medicines Agency ) has recommended granting a conditional marketing authorisation for the vaccine Comirnaty, developed by BioNTech and Pfizer, to prevent coronavirus disease 2019 ( COVI ...


The U.S. Food and Drug Administration ( FDA ) has issued an emergency use authorization ( EUA ) for the second vaccine for the prevention of coronavirus disease 2019 ( COVID-19 ) caused by severe acut ...


The Pfizer-BioNTech COVID-19 vaccine contains a nucleoside-modified messenger RNA ( modRNA ) encoding the viral spike glycoprotein ( S ) of SARS-CoV-2. Known risks The vaccine has been shown t ...